Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 673

1.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
2.

Measurement of relative lung perfusion with electrical impedance and positron emission tomography: an experimental comparative study.

Bluth T, Kiss T, Kircher M, Braune A, Bozsak C, Huhle R, Scharffenberg M, Herzog M, Roegner J, Herzog P, Vivona L, Millone M, Dössel O, Andreeff M, Koch T, Kotzerke J, Stender B, Gama de Abreu M.

Br J Anaesth. 2019 May 31. pii: S0007-0912(19)30367-8. doi: 10.1016/j.bja.2019.04.056. [Epub ahead of print]

PMID:
31160064
3.

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.

Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M.

Leukemia. 2019 May 24. doi: 10.1038/s41375-019-0491-z. [Epub ahead of print]

PMID:
31127149
4.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.

Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.

Haematologica. 2019 May 23. pii: haematol.2018.205534. doi: 10.3324/haematol.2018.205534. [Epub ahead of print]

5.

LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.

Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM.

EBioMedicine. 2019 Jun;44:126-137. doi: 10.1016/j.ebiom.2019.05.025. Epub 2019 May 16.

6.

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M.

Cancer Cell. 2019 May 13;35(5):721-737.e9. doi: 10.1016/j.ccell.2019.03.014. Epub 2019 May 2.

PMID:
31056398
7.

BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.

Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G.

J Clin Invest. 2019 Feb 21;130. pii: 120654. doi: 10.1172/JCI120654.

8.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.

Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S.

Cancer. 2019 Jun 1;125(11):1855-1866. doi: 10.1002/cncr.31986. Epub 2019 Feb 27.

PMID:
30811597
9.

Effects of Positive End-Expiratory Pressure and Spontaneous Breathing Activity on Regional Lung Inflammation in Experimental Acute Respiratory Distress Syndrome.

Kiss T, Bluth T, Braune A, Huhle R, Denz A, Herzog M, Herold J, Vivona L, Millone M, Bergamaschi A, Andreeff M, Scharffenberg M, Wittenstein J, Vidal Melo MF, Koch T, Rocco PRM, Pelosi P, Kotzerke J, Gama de Abreu M.

Crit Care Med. 2019 Apr;47(4):e358-e365. doi: 10.1097/CCM.0000000000003649.

PMID:
30676338
10.

An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML.

Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M.

Cancer Res. 2019 Mar 15;79(6):1165-1177. doi: 10.1158/0008-5472.CAN-18-0921. Epub 2019 Jan 23.

PMID:
30674535
11.

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ.

Blood. 2019 Mar 7;133(10):1011-1019. doi: 10.1182/blood-2018-10-879429. Epub 2018 Dec 7.

PMID:
30530801
12.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG.

Cancer. 2019 May 1;125(9):1470-1481. doi: 10.1002/cncr.31896. Epub 2018 Nov 30.

13.

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine.

Tabe Y, Saitoh K, Yang H, Sekihara K, Yamatani K, Ruvolo V, Taka H, Kaga N, Kikkawa M, Arai H, Miida T, Andreeff M, Spagnuolo PA, Konopleva M.

Sci Rep. 2018 Nov 15;8(1):16837. doi: 10.1038/s41598-018-35198-6.

14.

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H.

Cancer Discov. 2019 Mar;9(3):370-383. doi: 10.1158/2159-8290.CD-18-0774. Epub 2018 Nov 8.

PMID:
30409776
15.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD.

Blood Cancer J. 2018 Oct 19;8(11):98. doi: 10.1038/s41408-018-0134-z.

16.

Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis.

Le PM, Andreeff M, Battula VL.

Haematologica. 2018 Dec;103(12):1945-1955. doi: 10.3324/haematol.2018.197004. Epub 2018 Oct 18. Review.

17.

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.

Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2019 Jan;94(1):74-79. doi: 10.1002/ajh.25318. Epub 2018 Nov 15.

PMID:
30328139
18.

Early detection of transformation to BPDCN in a patient with MDS.

Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB.

Exp Hematol Oncol. 2018 Oct 6;7:26. doi: 10.1186/s40164-018-0117-6. eCollection 2018.

19.

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M.

Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018.

20.

ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway.

Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, Do KA, Ueno NT, Andreeff M, Battula VL.

Mol Cancer Ther. 2018 Dec;17(12):2689-2701. doi: 10.1158/1535-7163.MCT-18-0399. Epub 2018 Sep 20.

PMID:
30237308
21.

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.

Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G.

Am J Hematol. 2018 Oct;93(10):1245-1253. doi: 10.1002/ajh.25234. Epub 2018 Sep 26.

PMID:
30051599
22.

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.

Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F.

Am J Hematol. 2018 Sep;93(9):1136-1141. doi: 10.1002/ajh.25198. Epub 2018 Aug 31.

PMID:
30028037
23.

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.

Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA.

Nat Commun. 2018 Jul 10;9(1):2670. doi: 10.1038/s41467-018-04924-z.

24.

NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.

Griessinger E, Andreeff M.

Haematologica. 2018 Jun;103(6):921-923. doi: 10.3324/haematol.2018.193847. No abstract available.

25.

Oxidized analogs of Di(1H-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity.

Sanchez M, Xia Z, Rico-Bautista E, Cao X, Cuddy M, Castro DJ, Correa RG, Chen L, Yu J, Bobkov A, Ruvolo V, Andreeff M, Oshima RG, Matsuzawa SI, Reed JC, Zhang XK, Hansel D, Wolf DA, Dawson MI.

Oncotarget. 2018 May 18;9(38):25057-25074. doi: 10.18632/oncotarget.25285. eCollection 2018 May 18.

26.

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.

Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, Daver N, Andreeff M.

Haematologica. 2018 Oct;103(10):1642-1653. doi: 10.3324/haematol.2017.185082. Epub 2018 May 17.

27.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2019 Jan;60(1):37-48. doi: 10.1080/10428194.2018.1464158. Epub 2018 May 9.

PMID:
29741984
28.

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K.

J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.

29.

Role of MSC-derived galectin 3 in the AML microenvironment.

Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N Jr, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M.

Biochim Biophys Acta Mol Cell Res. 2018 Jul;1865(7):959-969. doi: 10.1016/j.bbamcr.2018.04.005. Epub 2018 Apr 12.

30.

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J.

Lancet Haematol. 2018 Apr;5(4):e136-e146. doi: 10.1016/S2352-3026(18)30021-8. Epub 2018 Mar 14.

PMID:
29550383
31.

Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival.

Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N Jr, Konopleva M, Andreeff M.

Haematologica. 2018 May;103(5):810-821. doi: 10.3324/haematol.2017.172429. Epub 2018 Mar 15.

32.

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.

Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M.

Cancer Res. 2018 May 15;78(10):2721-2731. doi: 10.1158/0008-5472.CAN-17-0949. Epub 2018 Feb 28.

33.

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.

Clin Cancer Res. 2018 May 15;24(10):2417-2429. doi: 10.1158/1078-0432.CCR-17-1556. Epub 2018 Feb 20.

34.

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.

Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R.

Oncotarget. 2017 Dec 12;9(4):4354-4365. doi: 10.18632/oncotarget.23150. eCollection 2018 Jan 12.

35.

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.

Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T.

Leuk Lymphoma. 2018 Sep;59(9):2238-2241. doi: 10.1080/10428194.2017.1422864. Epub 2018 Jan 17. No abstract available.

PMID:
29338567
36.

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group.

Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM.

Blood Adv. 2017 Aug 17;1(19):1546-1550. doi: 10.1182/bloodadvances.2017009019. eCollection 2017 Aug 22.

37.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.

Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

38.

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.

Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B.

Oncotarget. 2017 Nov 1;8(60):102150-102160. doi: 10.18632/oncotarget.22235. eCollection 2017 Nov 24.

39.

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12.

PMID:
29234845
40.

Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.

Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, Konopleva M, Andreeff M.

Cancer Cell. 2017 Dec 11;32(6):748-760.e6. doi: 10.1016/j.ccell.2017.11.003.

41.

Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia.

Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M.

Oncotarget. 2017 Jul 6;8(48):83354-83369. doi: 10.18632/oncotarget.19042. eCollection 2017 Oct 13.

42.

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.

Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM.

Haematologica. 2017 Dec;102(12):2048-2057. doi: 10.3324/haematol.2017.168856. Epub 2017 Sep 14.

43.

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.

Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J.

Neoplasia. 2017 Oct;19(10):772-780. doi: 10.1016/j.neo.2017.07.009. Epub 2017 Aug 30.

44.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

45.

Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells.

Zeng Z, Konopleva M, Andreeff M.

Methods Mol Biol. 2017;1633:75-86. doi: 10.1007/978-1-4939-7142-8_5.

PMID:
28735481
46.

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F.

Haematologica. 2017 Oct;102(10):1709-1717. doi: 10.3324/haematol.2017.168732. Epub 2017 Jul 20.

47.

AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth.

Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE, Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M.

JCI Insight. 2017 Jul 6;2(13). pii: 90036. doi: 10.1172/jci.insight.90036. eCollection 2017 Jul 6.

48.

High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.

Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M.

Haematologica. 2017 Sep;102(9):1537-1548. doi: 10.3324/haematol.2016.162230. Epub 2017 Jun 28.

49.

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.

Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8.

50.

IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells.

Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M.

Oncotarget. 2017 Jun 6;8(23):36936-36949. doi: 10.18632/oncotarget.16294.

Supplemental Content

Loading ...
Support Center